Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T2558 |
Cladribine
2-chlorodeoxyadenosine,克拉屈滨,2-Chloro-2′-deoxyadenosine,CldAdo,2CdA |
Apoptosis; Adenosine deaminase | Apoptosis; Metabolism |
Cladribine (2CdA) 是一种嘌呤核苷类似物,是具有口服活性的腺苷脱氨酶抑制剂。它能作为 DNA 合成的抑制剂,可阻断受损 DNA 的修复。它可抑制 DNA 甲基化,具有抗淋巴瘤活性,可研究血液恶性肿瘤和多发性硬化。 | |||
T36981 |
GSK 591 dihydrochloride
|
||
Potent and selective PRMT5 inhibitor (IC50 = 4 nM). Selective for PRMT5 over a panel of other PRMTs and lysine methyltransferases. Inhibits proliferation of mantle cell lymphoma (MCL) in vitro. To request the negative control for GSK 591, please fill out the SGC 2096 request form on the SGC website. | |||
T60706 |
LP-284
|
||
LP-284 可杀死实体瘤。LP-284 是一种有效的 DNA 烷化剂,可用于 DNA 修复受损的血液癌症研究,例如,套细胞淋巴瘤 (MCL) 。 | |||
T35481 |
DD 03-171
|
||
Potent and selective BTK Degrader (IC50 = 5.1 nM); degrades BTK in a proteasome- and CRBN-dependent manner. Suppresses BTK signaling and proliferation in mantle cell lymphoma (MCL) cells by degrading BTK, IKFZ1, and IKFZ3 (3 validated targets in B-cell malignancies). Also degrades Ibrutinib (Cat. No. 6813) -resistant C481S-BTK mutant cancer cells. Exhibits no binding against a panel of 468 kinases at 1 μM. Reduces tumor burden and extends survival in lymphoma patient-derived xenograft models. | |||
T70741 |
AZ-TAK1
|
||
AZ-Tak1 is a potent and a relatively selective inhibitor of TAK1 kinase activity, with an IC50 of 0.009 mM. AZ-Tak1 treatment decreased the level of p38 and ERK in mantle cell lymphoma cells, and induced apoptosis in a dose and time dependent manner, with an IC50 of 0.1–0.5 mM. Using the annexin-V and PI staining and FACS analysis, After 48 hours of incubation, AZ-Tak1 (0.1 mM) induced apoptosis in 28%, 34% and 86% of Mino, SP53, and Jeko cells, respectively, which was increased to 32%, 42%, and... |